Sandra Shotwell Ph.D.
Sandra has over 25 years of experience in early stage technology commercialization. She has co-founded three companies, and has done biotech deals for Stanford University, Oregon Health Sciences University, and the National Institutes of Health, where she founded and led the technology licensing program. Sandra is Board Chair of Elex Biotech, a company developing drugs to manage cardiac arrhythmia. She also was a Managing Partner of Alta Biomedical Group, a consulting firm focusing on the commercialization of innovative technology.
David Peyton Ph.D.
Chief Scientific Officer
David is a Professor of Chemistry at Portland State University. He has carried out research in areas ranging from NMR methods development to biological chemistry, and has been working on infectious disease and malaria drug action for over 15 years. His work on parasites began in 1992 with NMR-based studies of anti-malarial drug action.
Katherine Liebman Ph.D.
Director, Scientific & Regulatory
Katherine leads the DesignMedix regulatory and quality system programs. A skilled synthetic organic chemist, she also leads the Company’s efforts to design and synthesize novel compounds for the company's product pipeline, and to seek new product opportunities.